Co-Founder and CEO
Troy is the CEO and co-founder of ModoSpira. Influenced by two separate,
personal interactions with people living with COPD, Troy was moved by how
little had apparently changed in the 15 years separating those encounters,
particularly in the mindsets of those patients and how they approached their
condition…through inaction and resignation. Troy founded ModoSpira to reorient
people diagnosed with COPD to the fact that they live with a very treatable
condition, and to provide those people with all of the knowledge and tools to
improve their symptoms and quality of life. Troy assembled the brightest minds,
kindest hearts, and most inspiring souls, to finally offer people living with
COPD a clinically proven, customizable, affordable, and sustainable solution
for their treatment of COPD.
Ravi Kalhan, MD, MS
Co-founder and Chief Medical Officer
Ravi is the co-founder and CMO of ModoSpira, after having devoted his entire career to the
advancement of treatment and research in COPD. Ravi is Director of the Northwestern
University Asthma and COPD Program, and medical director of the pulmonary rehabilitation
program at the Rehabilitation Institute of Chicago, the nation's top rehabilitation
hospital. In these positions, Ravi manages the care for thousands of patients with
COPD and other chronic conditions. These experiences have formed the basis for what
ModoSpira provides to patients…evidence-based therapies proven to engage patients and
improve their symptoms and self-efficacy.
Ravi attended college at Brown University in Providence, RI where he majored in modern
American history. He subsequently entered medical school at Case Western Reserve
University School of Medicine and completed his internal medicine residency at the
Hospital of the University of Pennsylvania. He then moved to Chicago where he pursued
his fellowship training in Pulmonary and Critical Care Medicine at Northwestern Memorial
Hospital, and has been on the Northwestern University Feinberg School of Medicine
faculty since 2006. His research interests relate to respiratory epidemiology, in
particular identification of early risk factors that impact the vulnerability of
certain cigarette smokers to develop COPD. He is also involved in clinical trials of
new therapies for both asthma and COPD. He additionally serves as Chairman of the
Illinois COPD Coalition, a multidisciplinary group including representatives from
community-based organizations, public health departments, professional organizations,
patients, caregivers, healthcare providers, pharmaceutical companies and home healthcare
providers which has the goal of implementing sustainable solutions for reducing the
burden of COPD in Illinois. Ravi serves on the Board of Directors of the Respiratory
Health Association, the Medical and Scientific Advisory Committee of the COPD Foundation,
is an associate editor for Annals of the American Thoracic Society, and on the editorial
boards of the American Journal of Respiratory and Critical Care Medicine and Thorax.
VP of Business Development
Michael Skolnik leads the business development efforts for ModoSpira and has a deep commitment to easing the burdens of COPD and lung disease, having lost a family member to COPD and with other family members suffering from lung disease. Michael believes that ModoSpira provides the opportunity for all people living with COPD to better their condition and live a more normal life with less fear of exacerbation. He also understands the economic impact of COPD in his role as Managing Consultant with the Value Based Health Care Institute. The VBHCI is instrumental in developing and contracting effective managed care networks, recommending and implementing value based incentive models, collaborating with partners in implementing population health programs, and helping ACOs and Self-Funded Employer plans operationalize and go to market.
Michael brings two decades of experience designing and commercializing innovative commercial, Medicare and Managed Care solutions that empower providers and consumers to take a more active role in their health. Michael recently completed the contracting of a 4500-provider health plan for Canopy Health in the San Francisco Bay Area. Prior to joining the VBHCI, Michael served as chief executive officer for Sutter Health's Managed Care Systems and Director of Network Development and Management for Blue Cross and Blue Shield of MA. Michael believes that for change to occur within the health care system that there has to be a focus on tightly managing the care for the 17% chronic care patients who account for over 72% of the health care dollars spent in the United States. Michael earned a MS degree in Health Care and Business Administration from Trinity University.
Marisa Alcaro, DPT
VP of Intervention
If you’re one of our patients perspiring while performing one of our demanding
physiotherapy regimens, you have Marisa to blame. But if you’re one of our expert
patient graduates, thankful for improved symptoms and a renewed outlook on life,
well, you also have Marisa to thank. Marisa knows how to produce positive results in
patients’ symptoms and outlooks – she does it every day, providing pulmonary
rehabilitation therapy at the nation’s top-rated facility. Marisa earned a Doctor
in Physical Therapy degree from Northwestern University, and remains on their clinical
faculty teaching graduate students about cardiovascular and pulmonary dysfunction and
Tami has been keeping respiratory patients stable and healthy at home for almost
30 years as owner and operator of one of the Midwest’s premiere high-acuity,
respiratory-oriented skilled nursing agencies. Tami’s multi-disciplinary approach
was defining post-acute care coordination before the term was popular, and she has
designed some of the most innovative home-based respiratory programs in the country.
Though the clinical aspects of Modo Spira’s intervention were conceived and designed
by our board-certified pulmonologist, the way in which the intervention touches the
patients’ lives is based largely on the three decades of experience Tami has with
delivering complex care to patients in the comfort and safety of their own homes.
Mark T. Dransfield, MD
Mark Dransfield completed his MD degree at the University of North Carolina at
Chapel Hill followed by residency in internal medicine and fellowship in pulmonary
and critical care at the University of Alabama at Birmingham where he served as chief
fellow. He has been on the faculty at UAB since 2003 and is currently Associate
Professor of Medicine in the Division of Pulmonary, Allergy and Critical Care and
also a staff physician at the Birmingham VA Medical Center. He serves as the Medical
Director of the UAB Lung Health Center and the Medical Director of Pulmonary
Rehabilitation. He was named Top 10 Teacher in the Department of Medicine in
2006-2008 and in 2009 was a recipient of the Cobbs-Rutsky Award for Clinical
Excellence. He has been named one of America’s Best Doctors in 2010-2014.
He has served on the ATS Clinical Problems Assembly Program Committee since
2008 and is also a member of the guideline development committee for the American
College of Chest Physicians and Canadian Thoracic Society Evidence-based
Guidelines for the Prevention of Acute Exacerbations.
Dr. Dransfield’s primary clinical and research interest is chronic obstructive
pulmonary disease (COPD). He has particular interest in the care of patients
with advanced COPD and directs the UAB lung volume reduction surgery evaluation
process and the UAB/Centers for Medicare and Medicaid COPD Integrated Practice Unit.
He is Principal Investigator for multiple clinical trials at the UAB Lung Health
Center (LHC) including the NIH sponsored COPD Clinical Research Network studies,
COPDGene, and Spiromics as well as numerous phase II-IV pharma sponsored projects.
As Medical Director of the LHC he also oversees multiple translational research
projects focusing on airways disease. The LHC encompasses approximately 11,300
square feet of laboratory and clinical research space. The LHC is currently
conducting more than 20 clinical trials in COPD and asthma and houses cores in
Human Pulmonary Function, Recruitment, and Regulatory Support as well as a
Biospecimen Repository and has collaborations on campus for the performance of
research bronchoscopy, proteomics, synthetic chemistry, and murine pulmonary function
testing and specimen analysis. He has published over 80 research papers focusing on
COPD related epidemiology, co-morbid illness, pathophysiology and therapeutics.
MeiLan Han, MD, MS
MeiLan Han is an Associate Professor of Medicine in the Division of Pulmonary and Critical Care
at the University of Michigan. Dr. Han received her medical degree from the University of
Washington in Seattle, WA. She completed her residency in Internal Medicine and fellowship
in Pulmonary and Critical Care Medicine at the University of Michigan. Dr. Han has also
completed a Master's Degree program in Biostatistics and Clinical Study Design at the
University of Michigan School of Public Health. She is co-chair of the University of
Michigan COPD Quality Improvement Committee. She is also a member of several medical
organizations, including the American Thoracic Society and the European Respiratory Society.
She serves as an associate editor for the journal Thorax and serves on the editorial board for
the Journal of the COPD Foundation. She also serves on the scientific advisory committees for
the COPD Foundation, American Thoracic Society and American Lung Association as well as chairs
the Educational Materials committee for the COPD Foundation.
George R. Washko, MD, MMSc
George Washko is an Associate Professor of Medicine at Harvard Medical School and
staff pulmonologist at Brigham and Women’s Hospital. He completed his medical
school training at Georgetown University, medical residency at Beth Israel Deaconess
Medical Center, and then fellowship training in the Harvard Combined Pulmonary and
Critical Care Program. Dr. Washko has been on staff in the Pulmonary Division at
Brigham and Women’s Hospital since 2006 where his clinical responsibilities have
included attending in the Thoracic Surgery Intensive Care Unit as well as the
outpatient evaluation of patients for lung transplantation. He is also a clinical
investigator and has been active in several local, national, and international
therapeutic trials. His current focus is on quantitative image analysis and the
application of such tools to clinical care and investigation. He holds multiple
R01 awards in this area in addition to contracts to process scans from local,
national and international investigations such as the Framingham Heart Study and an
ongoing investigation of the effects of occupational exposure on lung function in China.